Lefeng International Inc U S A is categorized under Patent Medicines in Montclair, CA and active since 2011.
Lefeng International Inc U S A was established in 2011, and today employs 1 to 4, earning $100.000 to $499.999 per year. This is a Patent Medicines business, which does work in the B2B market, and is classified as a Patent Medicines, under code number 424210 by the NAICS.
If you are seeking more information, feel free to contact Yun Qian Bai at the company’s single location by writing to 4042 Mission Boulevard, Montclair, California CA 91763 or by phoning (909) 620-1326. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Lefeng International Inc U S A |
| Contact Person: | Yun Qian Bai |
| Address: | 4042 Mission Boulevard, Montclair, California 91763 |
| Phone Number: | (909) 620-1326 |
| Annual Revenue (USD): | $100.000 to $499.999 |
| Founded: | 2011 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Patent Medicines |
| SIC Code: | 5122 |
| NAICS Code: | 424210 |
| Share This Business: |
Lefeng International Inc U S A was started in 2011 to provide professional Patent Medicines under the SIC code 5122 and NAICS code 424210. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $100.000 to $499.999 per annum.
Feel free to contact Yun Qian Bai for inquiries that concern Lefeng International Inc U S A by calling the company number (909) 620-1326, as your correspondence is most welcome. Additionally, the physical location of the single location of Lefeng International Inc U S A can be found at the coordinates 34.056205,-117.716298 as well as the street address 4042 Mission Boulevard in Montclair, California 91763.
For its online presence, you may visit Lefeng International Inc U S A’s website at and engage with its social media outlets through on Twitter and on Facebook.